Current Status of Clinical Trials on Tau Immunotherapies

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

Cryo-EM structures of tau filaments from Alzheimer’s disease

Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061 · see citing works

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · see citing works

Transmission and spreading of tauopathy in transgenic mouse brain

Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803 · see citing works

Tau pathology and neurodegeneration

Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133 · see citing works

Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration

Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Structures of filaments from Pick’s disease reveal a novel tau protein fold

Falcon, B., Zhang, W., Murzin, A. G., Murshudov, G. N., Garringer, H. J., Vidal, R., Crowther, R. A., Ghetti, B. F., Scheres, S. H. W., & Goedert, M. (2018) · Nature · doi:10.1038/s41586-018-0454-y · Cited by 837 · see citing works

The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans

Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., et al. (2019) · Science · doi:10.1126/science.aav2546 · Cited by 813 · see citing works

Tau and neurodegenerative disease: the story so far

Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · see citing works

Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules

Falcon, B., Zivanov, J., Zhang, W., Murzin, A. G., Garringer, H. J., Vidal, R., Crowther, R. A., Newell, K. L., Ghetti, B. F., Goedert, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1026-5 · Cited by 703 · see citing works

Aβ Oligomers Cause Localized Ca ²⁺ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines

Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · see citing works

Post-translational modifications of tau protein: Implications for Alzheimer's disease

Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 645 · see citing works

Tau Kinetics in Neurons and the Human Central Nervous System

Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works

Neuronal activity regulates extracellular tau in vivo

Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131685 · Cited by 574 · see citing works

Trans-cellular Propagation of Tau Aggregation by Fibrillar Species

Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552 · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445 · see citing works

Post-translational modifications of tau protein in Alzheimer’s disease

Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437 · see citing works

Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains

Arakhamia, T., Lee, C. E., Carlomagno, Y., Kumar, M., Duong, D. M., Wesseling, H., Kundinger, S. R., Wang, K., Williams, D., Deture, M. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.027 · Cited by 400 · see citing works

<i>In Vivo</i> Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice

Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351 · see citing works

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works

Tau exon 10 alternative splicing and tauopathies

Liu, F., & Gong, C.-X. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-8 · Cited by 323 · see citing works

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory

Fà, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M. A., Puma, D. D. L., Chatterjee, I., Li, J., Saeed, F., et al. (2016) · Scientific Reports · doi:10.1038/srep19393 · Cited by 274 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works

Human secreted tau increases amyloid-beta production

Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230 · see citing works

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease

Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228 · see citing works

Constitutive secretion of tau protein by an unconventional mechanism

Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224 · see citing works

CSF biomarkers in frontotemporal lobar degeneration with known pathology

Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216 · see citing works

Propagation of Tau aggregates

Goedert, M., & Spillantini, M. G. (2017) · Molecular Brain · doi:10.1186/s13041-017-0298-7 · Cited by 213 · see citing works

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209 · see citing works

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

Collin, L., Bohrmann, B., Göpfert, U., Oroszlan‐Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 203 · see citing works

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation

McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201 · see citing works

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works

It’s all about tau

Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 195 · see citing works

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · see citing works

From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy

Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187 · see citing works

Tau passive immunization inhibits not only tau but also Aβ pathology

Dai, C., Tung, Y. C., Liu, F., Gong, C., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 186 · see citing works

Anti‐tau antibody reduces insoluble tau and decreases brain atrophy

Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185 · see citing works

Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

Castillo‐Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero‐Munoz, M. J., Lasagna‐Reeves, C. A., & Kayed, R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132477 · Cited by 180 · see citing works

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works

Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn‐mediated local protein translation

Li, C., & Götz, J. (2017) · The EMBO Journal · doi:10.15252/embj.201797724 · Cited by 178 · see citing works

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

Albert, M., Mairet‐Coello, G., Danis, C., Lieger, S., Caillierez, R., Carrier, S., Skrobala, E., Landrieu, I., Michel, A., Schmitt, M., et al. (2019) · Brain · doi:10.1093/brain/awz100 · Cited by 177 · see citing works

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168 · see citing works

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 163 · see citing works

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works

Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae

Albayram, Ö., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M. C., Driver, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 152 · see citing works

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease

Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147 · see citing works

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Höglinger, G. U., Litvan, I., Mendonça, N., Wang, D., Zheng, H., Rendenbach‐Mueller, B., Lon, H., Jin, Z., Fisseha, N., Budur, K. S., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 146 · see citing works

Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity

d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144 · see citing works

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

Sankaranarayanan, S., Barten, D. M., Vana, L., Devidze, N., Yang, L., Cadelina, G. W., Hoque, N., DeCarr, L. B., Keenan, S., Lin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125614 · Cited by 143 · see citing works

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies

Barthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139 · see citing works

Formation and Propagation of Tau Oligomeric Seeds

Gerson, J. E., & Kayed, R. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00093 · Cited by 137 · see citing works

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease

Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135 · see citing works

Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets

Li, T., Vandesquille, M., Koukouli, F., Dudeffant, C., Youssef, I., Lenormand, P., Ganneau, C., Maskos, U., Czech, C., Grueninger, F., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.019 · Cited by 133 · see citing works

Divergent CSF   alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery &amp; Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132 · see citing works

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

West, T., Hu, Y., Verghese, P. B., Bateman, R. J., Braunstein, J. B., Fogelman, I., Budur, K., Florian, H., Mendonca, N., & Holtzman, D. M. (2017) · PubMed · doi:10.14283/jpad.2017.36 · Cited by 132 · see citing works

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

Courade, J., Angers, R. C., Mairet‐Coello, G., Pacico, N., Tyson, K. L., Lightwood, D. J., Munro, R., McMillan, D., Griffin, R., BAKER, T. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1911-2 · Cited by 131 · see citing works

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement

Lee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125 · see citing works

Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120 · see citing works

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · see citing works

How much can business expect to profit from smoking cessation?,

Kristein, M. M. (1983) · Preventive Medicine · doi:10.1016/0091-7435(83)90245-1 · Cited by 116 · see citing works

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer, A., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O'Suilleabhain, P., et al. (2019) · Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 115 · see citing works

Distinct Therapeutic Mechanisms of Tau Antibodies

Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · see citing works

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100 · see citing works

Tau as a Therapeutic Target for Alzheimers Disease

Boutajangout, A., Sigurdsson, E. M., & Krishnamurthy, P. K. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717195 · Cited by 97 · see citing works

Characterization of tau oligomeric seeds in progressive supranuclear palsy

Gerson, J. E., Sengupta, U., Lasagna‐Reeves, C. A., Guerrero‐Munoz, M. J., Troncoso, J. C., & Kayed, R. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-73 · Cited by 95 · see citing works

Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I

Andoh, T., & Kuraishi, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-1169fje · Cited by 94 · see citing works

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 90 · see citing works

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants

Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90 · see citing works

Tau immunotherapies: Lessons learned, current status and future considerations

Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90 · see citing works

Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines

Xia, D., Li, C., & Götz, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.017 · Cited by 88 · see citing works

Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology

Yamada, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00667 · Cited by 84 · see citing works

Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases

Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83 · see citing works

Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice

Ittner, A., Bertz, J., Suh, L. S., Stevens, C. H., Götz, J., & Ittner, L. M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12821 · Cited by 81 · see citing works

The Neurotoxic Role of Extracellular Tau Protein

Sebastián‐Serrano, Á., de Diego-García, L., & Dı́az-Hernández, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040998 · Cited by 81 · see citing works

Evidence for neuronal expression of functional Fc (ε and γ) receptors

van der Kleij, H. P. M., Charles, N., Karimi, K., Mao, Y., Foster, J. A., Janssen, L. J., Yang, P. C., Kunze, W., Rivera, J., & Bienenstock, J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.054 · Cited by 78 · see citing works

Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes

Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B. R., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 78 · see citing works

Tau oligomers in cerebrospinal fluid in Alzheimer's disease

Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77 · see citing works

Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies

Kametani, F., Yoshida, M., Matsubara, T., Murayama, S., Saito, Y., Kawakami, I., Onaya, M., Tanaka, H., Kakita, A., Robinson, A., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.581936 · Cited by 76 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works

Passive immunotherapy of tauopathy targeting pSer413‐tau: a pilot study in mice

Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., & Tomiyama, T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.171 · Cited by 73 · see citing works

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

Krishnamurthy, P., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 71 · see citing works

Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice

Liu, W., Zhao, L., Blackman, B. A., Parmar, M. S., Wong, M. Y., Woo, T., Yu, F., Chiuchiolo, M. J., Sondhi, D., Kaminsky, S. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2016-16.2016 · Cited by 68 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67 · see citing works

Characterization of tau binding by gosuranemab

Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 64 · see citing works

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Congdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., González‐Calle, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 63 · see citing works

Antibody-DerivedIn VivoImaging of Tau Pathology

Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62 · see citing works

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., & LaFerla, F. M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.047 · Cited by 58 · see citing works

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57 · see citing works

Tau Immunotherapy

Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56 · see citing works

Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

Congdon, E. E., Chukwu, J. E., Shamir, D. B., Deng, J., Ujla, D., Sait, H. B. R., Neubert, T. A., Kong, X., & Sigurdsson, E. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.033 · Cited by 55 · see citing works

Targeting tauopathy with engineered tau-degrading intrabodies

Gallardo, G., Wong, C. H. Y., Hernandez, S. M. R., Mann, C. N., Lin, K., Leyns, C. E. G., Jiang, H., & Holtzman, D. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0340-6 · Cited by 55 · see citing works

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice

Vitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 54 · see citing works

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 53 · see citing works

Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau

Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 51 · see citing works

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49 · see citing works

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies

d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135774 · Cited by 48 · see citing works

[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU

Alam, R., Driver, D. A., Wu, S., Lozano, E., Key, S., Hole, J. T., Hayashi, M. L., & Lu, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.227 · Cited by 45 · see citing works

A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor

Han, P., Serrano, G. E., Beach, T. G., Caselli, R. J., Yin, J., Zhuang, N., & Shi, J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw105 · Cited by 44 · see citing works

Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice

Fernández‐Vizarra, P., López‐Franco, Ó., Mallavia, B., Higuera‐Matas, A., López-Parra, V., Ortiz-Muñoz, G., Ambrosio, E., Egido, J., Almeida, O. F. X., & Gómez‐Guerrero, C. (2012) · Brain · doi:10.1093/brain/aws195 · Cited by 42 · see citing works

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes

Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 42 · see citing works

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 39 · see citing works

Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice Studies

Dupré, E., Danis, C., Arrial, A., Hanoulle, X., Homa, M., Cantrelle, F., Merzougui, H., Colin, M., Rain, J., Buée, L., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00217 · Cited by 35 · see citing works

Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach

Shamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 33 · see citing works

MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice

Davtyan, H., Chen, W. W., Zagorski, K., Davis, J., Petrushina, I., Kazarian, K., Cribbs, D. H., Agadjanyan, M. G., Blurton-Jones, M., & Ghochikyan, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.020 · Cited by 30 · see citing works

Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging

Wu, Q., Lin, Y., Gu, J., & Sigurdsson, E. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.041 · Cited by 29 · see citing works

P1‐052: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI‐PHOSPHO‐TAU ANTIBODY JNJ‐63733657 IN HEALTHY SUBJECTS

Galpern, W. R., Mercken, M. H., Kolen, K. V., Timmers, M., Katrin, H., Janssens, L., Triana‐Baltzer, G., Kolb, H. C., Jacobs, T., Nandy, P., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.077 · Cited by 29 · see citing works

Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders

Spencer, B. J., Brüschweiler, S., Sealey‐Cardona, M., Rockenstein, E. M., Adame, A., Florio, J. B., Mante, M., Trinh, I., Rissman, R. A., Konrat, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1869-0 · Cited by 28 · see citing works

Fcγ receptors contribute to pyramidal cell death in the mouse hippocampus following local kainic acid injection

Suemitsu, S., Watanabe, M., Yokobayashi, E., Usui, S., Ishikawa, T., Matsumoto, Y., Yamada, N., Okamoto, M., & Kuroda, S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.004 · Cited by 27 · see citing works

Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68–71) improves spatial memory in okadaic acid induced tauopathy model rats

Subramanian, S., Savanur, G., & Madhavadas, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.101 · Cited by 25 · see citing works

Alzheimer's therapy development: A few points to consider

Sigurdsson, E. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.001 · Cited by 25 · see citing works

cis pT231-Tau Drives Neurodegeneration in Bipolar Disorder

Naserkhaki, R., Zamanzadeh, S., Baharvand, H., Nabavi, S. M., Pakdaman, H., Shahbazi, S., Vosough, M., Ghaedi, G., Barzegar, A., Mirtorabi, D., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00629 · Cited by 23 · see citing works

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models

Krishnaswamy, S., Huang, H.-W., Marchal, I. S., Ryoo, H. D., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104770 · Cited by 23 · see citing works

[P4–039]: PAN‐TAU ANTIBODY BIIB076 EXHIBITS PROMISING SAFETY AND BIOMARKER PROFILE IN CYNOMOLGUS MONKEY TOXICITY STUDY

Czerkowicz, J., Chen, W., Wang, Q. L., Shen, C., Wager, C. G., Stone, I., Stebbins, C., Lamb, M., Setser, J. J., Cantone, G., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1903 · Cited by 22 · see citing works

Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model

Shamir, D. B., Deng, Y., Wu, Q., Modak, S., Congdon, E. E., & Sigurdsson, E. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.602292 · Cited by 18 · see citing works

From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers

Hales, C. M., & Hu, W. T. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776522 · Cited by 15 · see citing works

Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice

Wu, Q., Bai, Y., Li, W., Congdon, E. E., Liu, W., Lin, Y., Ji, C., Gan, W., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105165 · Cited by 15 · see citing works

[O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD

Kerchner, G. A., Ayalon, G., Brunstein, F., Chandra, P., Datwani, A., Fuji, R. N., Manser, P. T., Vaze, A., Ward, M. R., Wildsmith, K. R., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.243 · Cited by 12 · see citing works

[O2–14–03]: TARGETING OF TOXIC AMYLOID‐BETA OLIGOMER SPECIES BY MONOCLONAL ANTIBODY PMN310: PRECISION DRUG DESIGN FOR ALZHEIMER's DISEASE

Kaplan, J. M., Silverman, J. M., Gibbs, E., Wang, J., Peng, X., Plotkin, S. S., & Cashman, N. R. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.225 · Cited by 9 · see citing works

In Vivo Imaging of Tauopathy in Mice

Krishnaswamy, S., Wu, Q., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., & Sigurdsson, E. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7816-8_32 · Cited by 9 · see citing works

P4‐696: QUANTIFICATION OF THE TAU MICROTUBULE BINDING REGION (MTBR) IN CEREBROSPINAL FLUID AND SUBSEQUENT VALIDATION OF TARGET ENGAGEMENT ASSAY FOR E2814, A NOVEL ANTI‐TAU THERAPEUTIC ANTIBODY

Horie, K., Takahashi, E., Aoyama, M., Nakatani, Y., Roberts, M., Staddon, J. M., de Silva, R., & Koyama, A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.060 · Cited by 6 · see citing works

Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model

Shamir, D. B., Deng, Y., & Sigurdsson, E. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7816-8_22 · Cited by 5 · see citing works

P1‐051: PARTICIPANT BASELINE CHARACTERISTICS IN PASSPORT, A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF BIIB092 FOR PROGRESSIVE SUPRANUCLEAR PALSY

Dam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Corvol, J., Lang, A. E., Grundman, M., Yang, L., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.076 · Cited by 3 · see citing works

Untitled work

(1997) · doi:10.1002/(sici)1097-4547(19970415)48:2

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation

Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516 · see citing works

Tau-targeting therapies for Alzheimer disease: Current status and future directions

Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371 · see citing works

Alzheimer's disease: From immunotherapy to immunoprevention

Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353 · see citing works

Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?

Tamagno, E., Guglielmotto, M., Vasciaveo, V., & Tabaton, M. (2021) · Antioxidants · doi:10.3390/antiox10091479 · Cited by 272 · see citing works

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217 · see citing works

Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials

Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197 · see citing works

Alzheimer's and Parkinson's disease therapies in the clinic

Chopade, P., Chopade, N., Zhao, Z., Mitragotri, S., Liao, R., & Suja, V. C. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10367 · Cited by 178 · see citing works

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues

Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 135 · see citing works

Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies

Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's &amp; Dementia · doi:10.1002/alz.13490 · Cited by 117 · see citing works

The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges

Zheng, H., Sun, H., Cai, Q., & Tai, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094969 · Cited by 65 · see citing works

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 62 · see citing works

Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline

Peretti, D. E., Boccalini, C., Ribaldi, F., Scheffler, M., Marizzoni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., & Garibotto, V. (2024) · Brain · doi:10.1093/brain/awae211 · Cited by 61 · see citing works

Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function

Miller, L. V. C., Papa, G., Vaysburd, M., Cheng, S., Sweeney, P. W., Smith, A. N., Franco, C. D. M. F., Katsinelos, T., Huang, M., Sanford, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.024 · Cited by 58 · see citing works

Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice

Gaikwad, S., Puangmalai, N., Sonawane, M., Montalbano, M., Price, R., Iyer, M. S., Ray, A., Moreno, S., & Kayed, R. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5958 · Cited by 46 · see citing works

Monoclonal Antibody Therapy in Alzheimer’s Disease

Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 43 · see citing works

Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly

Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 37 · see citing works

Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease

Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 38 · see citing works

Cellular and molecular mechanisms of pathological tau phosphorylation in traumatic brain injury: implications for chronic traumatic encephalopathy

Donison, N. S., Palik, J., Volkening, K., & Strong, M. J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00842-z · Cited by 39 · see citing works

Targeting epigenetics: A novel promise for Alzheimer’s disease treatment

Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 36 · see citing works

Tau and Alzheimer's disease: Past, present and future

Iqbal, K. (2024) · Cytoskeleton · doi:10.1002/cm.21822 · Cited by 35 · see citing works

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 32 · see citing works

Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound

Chen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 34 · see citing works

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease

Wang, Z., Wang, Q., Li, S., Li, X.-J., Yang, W., & He, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065183 · Cited by 35 · see citing works

Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity

Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 33 · see citing works

Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 32 · see citing works

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials

Feldman, H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Rizzo, S. J. S., Territo, P. R., Arnold, S. E., Ballard, C. G., Beher, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14250 · Cited by 27 · see citing works

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides

Singh, K., Gupta, J. K., Kumar, S., & Soni, U. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037275221240327042353 · Cited by 30 · see citing works

Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia

Jash, S., Banerjee, S., Cheng, S., Wang, B., Qiu, C., Kondo, A., Ernerudh, J., Zhou, X. Z., Lu, K. P., & Sharma, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41144-6 · Cited by 26 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies

Sigurdsson, E. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231238 · Cited by 27 · see citing works

Clathrin mediated endocytosis in Alzheimer’s disease: cell type specific involvement in amyloid beta pathology

Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26 · see citing works

Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care

Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 26 · see citing works

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Jabbari, E., & Duff, K. (2021) · Nature Medicine · doi:10.1038/s41591-021-01465-9 · Cited by 26 · see citing works

Therapeutic Effects of Hydrogen Gas Inhalation on Trimethyltin-Induced Neurotoxicity and Cognitive Impairment in the C57BL/6 Mice Model

Jeong, E., Bajgai, J., You, I.-S., Rahman, M. H., Fadriquela, A., Sharma, S., Kwon, H.-U., Lee, S. Y., Kim, C.-S., & Lee, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413313 · Cited by 26 · see citing works

Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease

Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24 · see citing works

Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects

Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 25 · see citing works

Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma

Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 24 · see citing works

New and emerging drug therapies for Alzheimer disease

Waite, L. M. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.021 · Cited by 22 · see citing works

Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer’s disease

Seplovich, G., Bouchi, Y., Vaccari, J. P. D. R., Pareja, J. C. M., Reisner, A., Blackwell, L. S., Mechref, Y. S., Wang, K., Tyndall, J. A., Tharakan, B., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00107 · Cited by 20 · see citing works

Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation

Li, L., Miao, J., Chu, D., Jin, N., Tung, Y. C., Dai, C., Hu, W. H., Gong, C., Iqbal, K., & Liu, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13970 · Cited by 17 · see citing works

New insights into the therapeutic approaches for the treatment of tauopathies

Singh, H., Das, A., Khan, M. M., & Pourmotabbed, T. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385288 · Cited by 18 · see citing works

Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer’s Disease

Reed-Geaghan, E. G., & Keller-Norrell, P. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417377 · Cited by 19 · see citing works

A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau

Luca, W., Foster, K., McClure, K., Ahlijanian, M. K., & Jefson, M. R. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.25 · Cited by 18 · see citing works

Protein Misfolding in Pregnancy: Current Insights, Potential Mechanisms, and Implications for the Pathogenesis of Preeclampsia

Fagla, B. M., & Buhimschi, I. A. (2024) · Molecules · doi:10.3390/molecules29030610 · Cited by 17 · see citing works

Protein disulfide isomerases as CSF biomarkers for the neuronal response to tau pathology

Wolzak, K., Vermunt, L., del Campo, M., Jorge‐Oliva, M., van Ziel, A. M., Li, K. W., Smit, A. B., Chen‐Ploktkin, A., Irwin, D. J., Lemstra, A. W., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12978 · Cited by 14 · see citing works

Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications

Menéndez‐González, M., Tamba, B.-I., Leclere, M., Mabrouk, M., Schreiner, T. G., Ciobanu, R. C., & Tomás‐Zapico, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030768 · Cited by 15 · see citing works

Preclinical characterization and IND‐enabling safety studies for PNT001, an antibody that recognizes cis‐pT231 tau

Foster, K., Manca, M., McClure, K. F., Koivula, P. P., Trojanowski, J. Q., Havas, D., Chancellor, S. E., Goldstein, L. E., Brunden, K. R., Kraus, A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13028 · Cited by 15 · see citing works

In vivo PET classification of tau pathologies in patients with frontotemporal dementia

Kubota, M., Endo, H., Takahata, K., Tagai, K., Suzuki, H., Onaya, M., Sano, Y., Yamamoto, Y., Kurose, S., Matsuoka, K., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae075 · Cited by 16 · see citing works

The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatmentsPreprint

Tai, H., Ma, H.-T., Huang, S.-C., Wu, M., Wu, C., Lai, Y., Li, Z., Margolin, R. A., Intorcia, A. J., Serrano, G. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.24.497452 · Cited by 15 · see citing works

Repurposing drugs: promising therapeutic approach against Alzheimer’s disease

Pattanaik, S., Ghose, A., Pakeeraiah, K., Paidesetty, S. K., Prusty, S. K., & Sahu, P. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102698 · Cited by 14 · see citing works

Updates on pharmacological treatment for Alzheimer’s disease

Tipton, P. W. (2023) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 16 · see citing works

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 17 · see citing works

A philosophy of science approach to the amyloid hypothesis of Alzheimer's disease

Daly, T. P. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16500 · Cited by 12 · see citing works

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer’s disease mouse model

Song, Y., Dai, C., Shinohara, M., Tung, Y. C., Zhou, S., Huang, W., Seffouh, A., Luo, Y., Willadsen, M., Jiao, Y., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.028 · Cited by 12 · see citing works

Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy

Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 12 · see citing works

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16 · see citing works

Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery

Lu, K. P., & Zhou, X. Z. (2024) · Science Signaling · doi:10.1126/scisignal.adi8743 · Cited by 11 · see citing works

Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials

Scott, I. A. (2024) · Age and Ageing · doi:10.1093/ageing/afae023 · Cited by 11 · see citing works

Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy

Karimi, N., Catak, F. B., Arslan, E. O., Saghazadeh, A., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109445 · Cited by 11 · see citing works

Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review

Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 10 · see citing works

Effective Nose-to-Brain Delivery of Blood-Brain Barrier Impermeant Anti-IL-1β Antibody via the Minimally Invasive Nasal Depot (MIND) Technique

Francesco, V. D., Chua, A. J. K., Bleier, B. S., & Amiji, M. M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c18679 · Cited by 10 · see citing works

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease

Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 10 · see citing works

Exploring the Formation of Polymers with Anti-Amyloid Properties within the 2′3′-Dihydroxyflavone Autoxidation Process

Sakalauskas, A., Janonienė, A., Žvinys, G., Mikalauskaitė, K., Žiaunys, M., & Smirnovas, V. (2022) · Antioxidants · doi:10.3390/antiox11091711 · Cited by 9 · see citing works

Using NMR diffusion data to validate MD models of disordered proteins: Test case of N-terminal tail of histone H4

Lebedenko, O. O., Salikov, V. A., Izmailov, S. A., Podkorytov, I. S., & Skrynnikov, N. R. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.11.020 · Cited by 9 · see citing works

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Frost, B. E., Rowe, J. B., Akinyemi, R., Abisambra, J. F., Ashton, N. J., Brendel, M., Buée, L., Butler, D., Carrillo, M. C., Chung, P. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70078 · Cited by 9 · see citing works

Focusing on oligomeric tau as a therapeutic target in Alzheimer’s disease and other tauopathies

Rayman, J. B. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2206561 · Cited by 9 · see citing works

De Novo Design of a β-Helix Tau Protein Scaffold: An Oligomer-Selective Vaccine Immunogen Candidate for Alzheimer’s Disease

(2023) · doi:10.1021/acschemneuro.3c00007 · Cited by 8 · see citing works

Tau post-translational modifications in Alzheimer's disease: Insights into pathogenesis, therapeutic strategies, and diagnostic advances

Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7 · see citing works

Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit

Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 7 · see citing works

Fully Human Bifunctional Intrabodies Achieve Graded Reduction of Intracellular Tau and Rescue Survival of MAPT Mutation iPSC-derived NeuronsPreprint

D’Brant, L., Rugenstein, N., Na, S. K., Miller, M. J., Czajka, T. F., Trudeau, N., Fitz, E. M., Tomaszek, L., Fisher, E. S., Mash, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.28.596248 · Cited by 8 · see citing works

Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies

Tutubala, T. E., Egunlusi, A. O., Fisher, D., Dube, A., & Joubert, J. (2025) · ACS Omega · doi:10.1021/acsomega.4c04887 · Cited by 9 · see citing works

Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer’s disease

Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 6 · see citing works

Time-Dependent Long-Term Effect of Memantine following Repetitive Mild Traumatic Brain Injury

Boucher, M. L., Conley, G. M., Morriss, N. J., Ospina-Mora, S., Qiu, J., Mannix, R., & Meehan, W. P., III (2024) · Journal of Neurotrauma · doi:10.1089/neu.2023.0423 · Cited by 6 · see citing works

Novel Role of Pin1-Cis P-Tau-ApoE Axis in the Pathogenesis of Preeclampsia and Its Connection with Dementia

Amabebe, E., Huang, Z., Jash, S., Krishnan, B., Cheng, S., Nakashima, A., Li, Y., Li, Z., Wang, R., Menon, R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines13010029 · Cited by 5 · see citing works

Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease

Panwar, A., Khan, M. I., Kumar, R., Kumar, R., Rai, S. K., & Kumar, A. (2024) · Advances in Alzheimer's Disease · doi:10.4236/aad.2024.133006 · Cited by 4 · see citing works

Strategies for translating proteomics discoveries into drug discovery for dementia

Halder, A., & Drummond, E. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373681 · Cited by 3 · see citing works

Hope or hype? Aducanumab as a magic bullet for Alzheimer’s disease

Lin, W., Xiao, C., & Salton, S. R. (2022) · BIO Integration · doi:10.15212/bioi-2021-0034 · Cited by 3 · see citing works

Increased tau expression in the APOE4 blood-brain barrier model is associated with reduced anti-tau therapeutic antibody delivery in vitroPreprint

Wasielewska, J. M., Bajracharya, R., Johnston, R. L., Chaves, J. C. S., Pébay, A., Oikari, L. E., Götz, J., Nisbet, R. M., & White, A. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563706 · Cited by 2 · see citing works

Concussive injuries induce neuronal stress-dependent tau mislocalization to dendritic spines with acrolein and functional network alteration in TBI-on-a-chip

Rogers, E. A., Diorio, T. C., Beauclair, T., Martinez, J., Mufti, S. J., Kim, D., Krishnan, N., Rayz, V. L., & Shi, R. (2025) · Lab on a Chip · doi:10.1039/d5lc00067j · Cited by 2 · see citing works

A nose for tau

Meftah, S., Durrant, C. S., & Spires‐Jones, T. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6489 · Cited by 2 · see citing works

Therapeutic approaches in proteinopathies

Nabi‐Afjadi, M., Dabirmanesh, B., & Uversky, V. N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.008 · Cited by 2 · see citing works

Identification of GABBR2 as a diagnostic marker and its association with Aβ in Alzheimer's disease

Li, H., Fan, Y., Chen, C., Xu, Y., Wang, X., & Liu, W. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102035 · Cited by 1 · see citing works

Tau Pathology in Alzheimer's Disease: Bridging Molecular Mechanisms and Targeted Therapies

Dahiya, M., Yadav, M., Kumar, A., & Goyal, C. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273376581250626003322 · Cited by 1 · see citing works

In the Slip Stream of Amyloid: The Tau and Tangle Hypothesis

Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_12 · Cited by 1 · see citing works

Terapéutica con anticuerpos monoclonales en la enfermedad de Alzheimer

Maliza-Moposita, J. A., & Salazar-Garcés, L. F. (2024) · MQRInvestigar · doi:10.56048/mqr20225.8.3.2024.2739-2760 · Cited by 1 · see citing works

The Importance of Vaccines in Preventing Impending Alzheimer’s Epidemic

Tripathi, S., Sharma, Y., & Kumar, D. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871357356250325071712 · Cited by 1 · see citing works

Neuron-specific resilience to proteostatic stress

Wolzak, K. (2023) · doi:10.5463/thesis.349

Measuring Antibody-Mediated Tau Fibril Uptake in Microglia by Flow Cytometry

Funk, K. E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_23

Deciphering the molecular and neuropathological dimensions of dementia

Dutta, S., Bhattacharjee, P., Noori, S., Adhikari, N., Dule, S., Soyel, M. I., Besra, M., Borah, S., & Gupta, P. (2025) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2025.05.002

Antibodies targeting amyloid-β and Tau oligomers in Alzheimer’s disease

Chinnathambi, S., Rangappa, N., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.002

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Brown, C. M., Brooks, J. K., Kelly, L., Vroom, M. M., Longo, M., Dodart, J., Carare, R. O., & Boyd, J. D. (2025) · Brain Pathology · doi:10.1111/bpa.70056

Expanding landscape of tau pathology in neurological disorders: A narrative review guiding diagnostic development and targeted therapeutics

Yakubu, A., Atafo, G., Nwaze, C., Bakare, T., Adeniyi, T. O., Alare, K. P., Oladele, A., & Solagbade, O. (2026) · NeuroMarkers · doi:10.1016/j.neumar.2026.100167 · Cited by 1 · see citing works

Im Windschatten von Amyloid: die Tau-und-Tangle-Hypothese

Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_12

Modern experimental strategies for the therapy of Alzheimer's disease and other tauopathies: molecular mechanisms, targeted approaches and prospects for clinical application

Maslii, V. P., Suprun, T. I., & Beiresh, Y. V. (2026) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2026-30(1)-29

Recent Advances in Drug Development for the Management of Alzheimer’s Disease

Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014

Challenges in recent Alzheimer's disease therapeutic approaches

Kim, C.-H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45844-6.00017-2

Passive immunotherapy in Alzheimer’s disease: biomarkers, biological staging, and emerging therapeutic strategies

Surhan, A., Oad, J., Kumar, B., Memon, S. N., Essrani, C., Muhammad, F., Kashif, S. N., Abbas, S. M. I., Ameen, T. B., Sauleh, A., et al. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01263-5

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies

Sigurdsson, E. M. (2024) · Advances in Alzheimer's disease · doi:10.3233/aiad240010 · Cited by 1 · see citing works

Tau Immunotherapy

Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56 · see citing works

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works